EGFR and colorectal carcinoma: Cetuximab, a monoclonal antibody blocking the interaction between EGFR and its ligands, inhibits the downstream RAS signaling cascade and ERK activation in CRC therapy, and another EGFR‐neutralizing antibody, panitumumab, is available 8.